Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...
Aramark (ARMK) is expected to report $0.49 for 4Q. Astria Therapeutics Inc (ATXS) is expected to report $-0.44 for 3Q. Bellerophon Therapeutics Inc (BLPH) is expected to report for 3Q. Black Diamond ...